title: 25-hydroxyvitamin d and severity of Parkinson's disease.
abstract: Introduction. A role for vitamin D deficiency in Parkinson's disease (PD) has recently been proposed. Given the growing body of evidence for the association of vitamin D with several neurodegenerative disorders and unavailability of any published study in the Middle East, the present study is aimed to determine the associations of circulating 25-hydroxyvitamin D (25OHD) levels with the severity of PD in an Iranian sample. Methods. In 109 patients, the severity of PD was evaluated by using Hoehn & Yahr (HR) stages and Unified Parkinson's Disease Rating Stage (UPDRS) Part III compared with 25OHD level in a double-blind and cross-sectional study. Results. Mean ± SD levels of 25OHD were 28.5 ± 1.4 and 27.1 ± 1.5, for males and females, respectively. Also, 38.4% of the patients showed deficiency levels of 25OHD (<20 ng/mL), and 72.8% had insufficient levels (<30 ng/mL). High prevalence of 25OHD insufficiency in subjects with early disease was not associated with HR stage and UPDRS scores even after multivariate adjustment for possible confounders including disease duration. Conclusions. These findings are consistent with the possibility that vitamin D status does not seem to deteriorate during the early disease stages of PD. Further studies are needed to reveal the natural role and significance of vitamin D insufficiency in PD.
authors: Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, 8174675731 Isfahan, Iran ; Department of Neurology, Medical School, Isfahan University of Medical Sciences, 8174675731 Isfahan, Iran.
authors: Ahmad
authors: A
authors: Chitsaz
authors: Mohammad
authors: M
authors: Maracy
authors: Keivan
authors: K
authors: Basiri
authors: Maryam
authors: M
authors: Izadi Boroujeni
authors: Amir Pouya
authors: AP
authors: Tanhaei
authors: Marzieh
authors: M
authors: Rahimi
authors: Rokhsareh
authors: R
authors: Meamar
references: Neurology. 1997 Nov;49(5):1273-8
references: 9371907
references: Brain Res Mol Brain Res. 1996 Feb;36(1):193-6
references: 9011759
references: Endocr Rev. 2005 Aug;26(5):662-87
references: 15798098
references: N Engl J Med. 2007 Jul 19;357(3):266-81
references: 17634462
references: Am J Public Health. 2006 Feb;96(2):252-61
references: 16380576
references: Am J Clin Nutr. 2004 Sep;80(3):752-8
references: 15321818
references: Heart Fail Rev. 2006 Mar;11(1):25-33
references: 16819575
references: Am J Prev Med. 2007 Mar;32(3):210-6
references: 17296473
references: Rev Neurol (Paris). 2010 Jan;166(1):1-4
references: 19910010
references: Recent Results Cancer Res. 2007;174:225-34
references: 17302200
references: Neurology. 2001 Nov;57(10 Suppl 3):S11-26
references: 11775596
references: Mov Disord. 2012 Feb;27(2):264-71
references: 22213340
references: Anticancer Res. 2009 Sep;29(9):3713-20
references: 19667169
references: J Chem Neuroanat. 2005 Jan;29(1):21-30
references: 15589699
references: J Nutr. 2006 Apr;136(4):1126-9
references: 16549493
references: Mov Disord. 2007 Mar 15;22(4):461-8
references: 17230473
references: Mov Disord. 2005 Dec;20(12):1598-603
references: 16114020
references: Arch Neurol. 2008 Oct;65(10):1348-52
references: 18852350
references: Arch Neurol. 2010 Jul;67(7):808-11
references: 20625085
references: J Health Popul Nutr. 2011 Apr;29(2):149-55
references: 21608424
references: Arch Neurol. 2011 Mar;68(3):314-9
references: 21403017